Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.
about
Screening for prostate cancerScreening for prostate cancerMortality results from a randomized prostate-cancer screening trialScreening for prostate cancer: systematic review and meta-analysis of randomised controlled trialsThe Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerCancer biomarkersValidation of proposed prostate cancer biomarkers with gene expression data: a long road to travelTumour biomarkers: homeostasis as a novel prognostic indicatorShiftwork and prostate-specific antigen in the National Health and Nutrition Examination SurveyRandomised prostate cancer screening trial: 20 year follow-upDiscussing uncertainty and risk in primary care: recommendations of a multi-disciplinary panel regarding communication around prostate cancer screeningPrimary care physicians' reported use of pre-screening discussions for prostate cancer screening: a cross-sectional surveyClinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic diseaseValidation of the group-based medical mistrust scale among urban black menIn-depth proteomic analyses of direct expressed prostatic secretions.Association of urinary phytoestrogen concentrations with serum concentrations of prostate-specific antigen in the National Health and Nutrition Examination Survey.Proteomics in prostate cancer biomarker discovery.Comparison between US Preventive Services Task Force recommendations and Medicare coverage.RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization.Measuring low-value care in Medicare.The Japanese guideline for prostate cancer screening.Correlates of colorectal cancer screening adherence among men who have been screened for prostate cancer.Prostate biopsy for the interventional radiologistUnderstanding preventive behaviors among mid-Western African-American men: a pilot qualitative study of prostate screeningRisk prediction of complex diseases from family history and known susceptibility loci, with applications for cancer screening.A dual-reporter, diagnostic vector for prostate cancer detection and tumor imaging.Knowledge and attitude of the population toward cancer prostate Riyadh, Saudi Arabia.PURLs: PSA testing: when it's useful, when it's not.The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.Cancer surveillance in patients with primary sclerosing cholangitis.Association of MnSOD AA Genotype with the Progression of Prostate Cancer.Tumor-suppressive microRNA-497 targets IKKβ to regulate NF-κB signaling pathway in human prostate cancer cellsRemaining Life Expectancy Measurement and PSA Screening of Older Men.Prostate cancer screening trends in a large, integrated health care system.Reconciling primary care and specialist perspectives on prostate cancer screening.Biopsy follow-up of prostate-specific antigen tests.Population-based patterns and predictors of prostate-specific antigen screening among older men in the United StatesThe impact of PSA testing frequency on prostate cancer incidence and treatment in older men.Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?Five-year downstream outcomes following prostate-specific antigen screening in older men
P2860
Q24201690-7BF94C0F-97FB-4C1F-9D65-789FFDDF33A3Q24245476-535C2793-2D75-4C37-BF99-41C37A342866Q24601536-A3027404-3AC3-4F22-B835-8355C621FE65Q24608493-CA68030B-28B3-431E-A826-E83424341A4CQ26738703-6A650C96-1292-4DB2-9DAF-50A437A89C7FQ26864429-1D1E3005-6055-44EA-83BC-1CC3B717CE86Q27001399-7CF3F81C-800B-4110-BE9B-34C40023F758Q28069898-B0CE5F4B-83B5-404F-9ECD-B46F8CA5AC9BQ28392746-E2D5CDA2-BEB2-484D-9AF5-ACD33B2227DCQ28741447-42980B07-49D8-4DE0-A145-07B577DE4E3DQ30551064-60844F77-6224-4195-BB0E-4E84C92C7DFBQ33419499-EE0895EE-2992-42F3-A396-AB6060E3685FQ33449075-B1F39A67-7ACE-4243-B303-251182DBBF28Q33848891-FEF22DE0-0F00-414A-9774-F2A0D82855E8Q33849273-60C2333D-51B9-4065-811B-F065F1C2B45DQ33862301-418FEA2D-3A0F-4317-95D0-3B0773C623D0Q34096086-993D89AA-3086-477B-90BF-A72460BDCC98Q34496369-1B02DCCF-B645-4D3F-BF86-DFB74A9F2D02Q34517369-84AE8D06-E5F2-422D-B7A5-416F83176C19Q34562997-E5227D9B-CEC3-4696-9379-4192244CC6C7Q34606240-6A383FE6-38AE-4AC7-8B50-661EAC4C7D9AQ34995422-1DAB5C03-E163-4C36-9F70-F4DF7183352CQ35019408-D777827B-89B1-46F3-8127-FC87DD6D62C4Q35087248-D523CBD3-4438-48A0-AF1A-DAA44023E203Q35136955-E59A611A-1ACA-4668-A591-B57B1D207857Q35151488-80011DE6-8C26-4198-B19C-D7FC16B81E9AQ35218345-995DF543-7CE4-4CE1-992A-022B33A7E570Q35247523-03EF5C8A-BD35-4881-8C6E-3467308F1F66Q35261674-B23E9C07-CA2A-4851-A92B-FFE4CC5B3B1BQ35490961-DFB3064E-E7FD-476A-BB93-7C6A384D5DE3Q35683992-F58D1D64-B523-4D8D-A2C2-845A90DB273FQ35835265-9A463665-2944-4DD6-8D9E-7ED2C85B66FDQ36073250-B1150A6B-3863-4CC3-BEB0-53A949E12EB1Q36235155-7DC6014F-AD1C-4E7D-93BA-2C5E0797B0D7Q36392498-7846AF78-7CEE-4D5D-A7A0-A5E9194F9798Q36567436-96CEF517-795D-49DE-9070-3CCE9E4E6573Q36767094-060152D4-DB1E-4B16-87A9-BB56C99C18ACQ36831317-D063CBD0-89A7-4BCA-B1BB-D4CE8CF36B5BQ36883768-618A9573-5DF3-4556-84B8-CE2D639D6529Q37017183-37E57241-1A11-447B-BEA3-882951254A8F
P2860
Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Benefits and harms of prostate ...... reventive Services Task Force.
@ast
Benefits and harms of prostate ...... reventive Services Task Force.
@en
type
label
Benefits and harms of prostate ...... reventive Services Task Force.
@ast
Benefits and harms of prostate ...... reventive Services Task Force.
@en
prefLabel
Benefits and harms of prostate ...... reventive Services Task Force.
@ast
Benefits and harms of prostate ...... reventive Services Task Force.
@en
P2093
P1476
Benefits and harms of prostate ...... reventive Services Task Force.
@en
P2093
Kenneth Lin
Robert Lipsitz
Supriya Janakiraman
Therese Miller
U.S. Preventive Services Task Force
P304
P356
10.7326/0003-4819-149-3-200808050-00009
P407
P577
2008-08-01T00:00:00Z